EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials

Sujata Purja, Yomna Elghanam, Eunyoung Kim

Infection · 2026-06 · 54 (3) · 1299-1318

DOI: 10.1007/s15010-026-02745-7 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Infection, online erschienen am 24.03.2026. Verfasst von Sujata Purja und 2 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang Un…. Hauptthemen laut MEDLINE: Vancomycin, Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Soft Tissue Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Food and Drug Safety of South Korea, Chung-Ang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Vancomycin is the standard therapy for suspected or confirmed Methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infection (SSTI). Although newer anti-MRSA agents claim improved efficacy and safety, evidence in microbiologically confirmed MRSA-SSTI remains limited and heterogenous. Thus, this study aimed to systematically compare the efficacy and safety of alternative agents versus vancomycin in adults with confirmed MRSA-SSTI. METHODS: Three databases were searched until August 05, 2025, to retrieve randomized controlled trials (RCTs) from published meta-analyses evaluating vancomycin versus alternatives involving patients with MRSA-confirmed SSTI. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated using random-effects model. The study is registered in PROSPERO (CRD420251119756). RESULTS: From 28 meta-analyses, 39 RCTs (n = 20,285; 2,662 patients with MRSA-confirmed SSTI receiving alternative agents and 2,322 receiving vancomycin) were included. No significant difference in clinical success was observed between groups (RR: 1.012, 95% CI: 0.992-1.032; prediction interval: 0.994-1.030). Although alternatives showed modestly higher microbiological success (RR: 1.058, 95% CI 1.001-1.119; prediction interval: 0.895-1.250), the effect lost significance after publication bias adjustment. Alternative agents had significantly lower dermatologic but higher gastrointestinal and hematological risk. Tigecycline had higher adverse events (RR: 1.090, 95% CI: 1.019-1.166), and telavancin had higher drug discontinuation (RR: 1.405, 95% CI: 1.105-1.786). CONCLUSION: Despite the growth of newer anti-MRSA agents, vancomycin remains clinically comparable for MRSA-confirmed SSTI, with apparent microbiological advantages of alternatives tempered by potential publication bias. Varying safety and pharmacological profiles of these agents emphasize the importance of individualized treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsSoft Tissue InfectionsStaphylococcal Skin InfectionsHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Adverse eventMRSAMeta-analysisSSTIVancomycin

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea.
  • Central Research Centre of Epigenome Based Platform and Its Application for Drug Development, College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea.
  • Data Science, Evidence-Based and Clinical Research Laboratory, Department of Health, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea. eykimjcb777@cau.ac.kr.
  • Central Research Centre of Epigenome Based Platform and Its Application for Drug Development, College of Pharmacy, Chung-Ang University, Seoul, 06974, Republic of Korea. eykimjcb777@cau.ac.kr.

Förderung

  • National Research Foundation of Korea
  • Ministry of Food and Drug Safety of South Korea
  • Chung-Ang University

Zitieren

APA

Purja, S., Elghanam, Y., & Kim, E. (2026). Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials. Infection, 54(3), 1299-1318. https://doi.org/10.1007/s15010-026-02745-7

Vancouver

Purja S, Elghanam Y, Kim E. Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials. Infection. 2026;54(3):1299-1318. doi:10.1007/s15010-026-02745-7

BibTeX
@article{Purja2026,
  author = {Purja, Sujata and Elghanam, Yomna and Kim, Eunyoung},
  title = {Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials},
  journal = {Infection},
  year = {2026},
  volume = {54},
  number = {3},
  pages = {1299--1318},
  doi = {10.1007/s15010-026-02745-7}
}
Kostenlos starten →